CO7190233A2 - Sistema y método para la determinación automatizada de la efectividad relativa de candidatos de fármaco anti-cancerígenos - Google Patents
Sistema y método para la determinación automatizada de la efectividad relativa de candidatos de fármaco anti-cancerígenosInfo
- Publication number
- CO7190233A2 CO7190233A2 CO14265404A CO14265404A CO7190233A2 CO 7190233 A2 CO7190233 A2 CO 7190233A2 CO 14265404 A CO14265404 A CO 14265404A CO 14265404 A CO14265404 A CO 14265404A CO 7190233 A2 CO7190233 A2 CO 7190233A2
- Authority
- CO
- Colombia
- Prior art keywords
- optical density
- well
- cancer cells
- drug
- well plate
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/59—Transmissivity
- G01N21/5907—Densitometers
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Theoretical Computer Science (AREA)
- Computing Systems (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Databases & Information Systems (AREA)
- Software Systems (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Se provee un sistema de computadora para determinarla efectividad relativa de fármacos anti-cancerígenos. Lainterfase tiene opciones seleccionables, incluyendo una opción para manejar los parámetros de prueba del fármaco, ypermite al usuario la selección de parámetros de prueba defármaco deseados con relación a una placa con pocillosvirtual asociada con una placa de pocillos física de unespectrofotómetro. El sistema de computadora causa que elespectrofotómetro inicie una prueba de fármaco, en donde laplaca de pocillos física incluye al menos un pocillo deprueba que contiene células cancerígenas viables; y al menosun fármaco candidato en una concentración predeterminada; yal menos un pocillo de control con las células cancerígenasviables sola. El sistema registra la densidad óptica delpocillo a una longitud de onda predeterminada a intervalos detiempo seleccionados por una duración de tiempo seleccionada,y almacena las mediciones de la densidad óptica y tiempo enla base de datos. Se calcula un valor de actividad de lasmediciones de la densidad óptica y tiempo, y se despliega unacorrelación entre el valor de la actividad y la habilidad delfármaco candidato para inducir apoptosis en las célulascancerígenas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641610P | 2012-05-02 | 2012-05-02 | |
| US13/803,623 US9476871B2 (en) | 2012-05-02 | 2013-03-14 | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7190233A2 true CO7190233A2 (es) | 2015-02-19 |
Family
ID=49514877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14265404A CO7190233A2 (es) | 2012-05-02 | 2014-12-02 | Sistema y método para la determinación automatizada de la efectividad relativa de candidatos de fármaco anti-cancerígenos |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9476871B2 (es) |
| EP (2) | EP4134962A1 (es) |
| JP (1) | JP6365988B2 (es) |
| KR (1) | KR102028711B1 (es) |
| CN (1) | CN104412270B (es) |
| AU (2) | AU2013256248B2 (es) |
| BR (1) | BR112014027287A2 (es) |
| CA (1) | CA2872109C (es) |
| CL (1) | CL2014002981A1 (es) |
| CO (1) | CO7190233A2 (es) |
| CR (1) | CR20140551A (es) |
| CU (1) | CU20140125A7 (es) |
| HK (1) | HK1203670A1 (es) |
| IL (1) | IL235455B (es) |
| MX (1) | MX345540B (es) |
| NI (1) | NI201400128A (es) |
| NZ (1) | NZ702526A (es) |
| PE (1) | PE20150299A1 (es) |
| PH (1) | PH12014502687A1 (es) |
| RU (1) | RU2014148543A (es) |
| SG (1) | SG11201407141VA (es) |
| TW (1) | TWI605413B (es) |
| WO (1) | WO2013166233A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9476871B2 (en) * | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
| KR20150035537A (ko) * | 2012-05-15 | 2015-04-06 | 디아테크 온콜로지, 엘엘씨 | 종양 세포 분리/정제 프로세스 및 이의 사용 방법들 |
| US9460407B2 (en) * | 2013-05-03 | 2016-10-04 | Sap Se | Generating graphical representations of data |
| WO2015171848A2 (en) * | 2014-05-08 | 2015-11-12 | Diatech Oncology, Llc | Synergism and antagonism between multiple anti-cancer agents determined by mick assay |
| JP6521528B2 (ja) * | 2016-04-18 | 2019-05-29 | 富士フイルム株式会社 | 代替医薬品検索装置及び代替医薬品検索方法 |
| US11151604B2 (en) * | 2016-06-10 | 2021-10-19 | International Business Machines Corporation | Revenue management using dynamic customer selection |
| CN110047562B (zh) * | 2019-05-14 | 2021-04-27 | 上海上药第一生化药业有限公司 | 一种基于酶活力测定法的效价检测的信息化结构和方法 |
| US20200388355A1 (en) * | 2019-06-07 | 2020-12-10 | Cary A. Presant | Method and devices for direct apoptosis assay of purified cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5068181A (en) | 1989-12-01 | 1991-11-26 | Akzo N.V. | Method of monitoring reagent delivery in a scanning spectrophotometer |
| US5356793A (en) | 1990-03-15 | 1994-10-18 | Nitta Gelatin Inc. | Method for testing the sensitivity of anticancer drug |
| US6077684A (en) | 1996-11-14 | 2000-06-20 | Vanderbilt University | Automated assay for measuring apoptosis in cell culture |
| CN1220395A (zh) * | 1997-12-15 | 1999-06-23 | 中国科学院生物物理研究所 | 一种基于微量元素分布特征的抗癌药物筛选方法 |
| US6448030B1 (en) | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| WO2002040702A2 (en) * | 2000-11-09 | 2002-05-23 | Vanderbilt University | Methods for the treatment of cancer and other diseases and methods of developing the same |
| AU2002239771A1 (en) | 2000-11-13 | 2002-06-18 | Vanderbilt University | Methods of predicting chemotherapy response |
| WO2002058533A2 (en) | 2000-11-17 | 2002-08-01 | Slanetz Alfred E | Process for determining target function and identifying drug leads |
| AU2002238874A1 (en) | 2002-03-13 | 2003-09-22 | F.Hoffmann-La Roche Ag | Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors |
| US6900058B2 (en) | 2003-03-11 | 2005-05-31 | Bionostics, Inc. | Control solution for photometric analysis |
| US8021611B2 (en) * | 2005-04-09 | 2011-09-20 | ProteinSimple | Automated micro-volume assay system |
| CN1954887A (zh) * | 2005-10-28 | 2007-05-02 | 中国科学院大连化学物理研究所 | 一种体外抗癌药物筛选模型的制备方法 |
| US7736905B2 (en) * | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
| KR100721927B1 (ko) | 2006-10-31 | 2007-05-28 | 이수앱지스 주식회사 | 암조직에서 암세포를 분리하는 방법 |
| GB2474613A (en) | 2008-07-10 | 2011-04-20 | Nodality Inc | Methods and apparatus related to management of experiments |
| US20120224053A1 (en) * | 2009-06-17 | 2012-09-06 | Board Of Regents, The University Of Texas System | Method and apparatus for quantitative microimaging |
| KR101533469B1 (ko) | 2010-02-03 | 2015-07-02 | 연세대학교 산학협력단 | Ｒａｓ의 Ｔｈｒ-144번과 Ｔｈｒ-148번의 인산화의 감지를 통한 암 진단 방법, 항암제 스크리닝 및 약효테스트 방법 |
| US20110244503A1 (en) * | 2010-03-31 | 2011-10-06 | Perree Mathieu | System and Method for Anti-Cancer Drug Candidate Evaluation |
| US8475739B2 (en) * | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
| US9476871B2 (en) * | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
| KR20150035537A (ko) | 2012-05-15 | 2015-04-06 | 디아테크 온콜로지, 엘엘씨 | 종양 세포 분리/정제 프로세스 및 이의 사용 방법들 |
-
2013
- 2013-03-14 US US13/803,623 patent/US9476871B2/en active Active
- 2013-04-30 TW TW102115445A patent/TWI605413B/zh active
- 2013-05-02 AU AU2013256248A patent/AU2013256248B2/en not_active Ceased
- 2013-05-02 EP EP22180904.9A patent/EP4134962A1/en not_active Withdrawn
- 2013-05-02 KR KR1020147033937A patent/KR102028711B1/ko active IP Right Grant
- 2013-05-02 PE PE2014001938A patent/PE20150299A1/es not_active Application Discontinuation
- 2013-05-02 NZ NZ702526A patent/NZ702526A/en not_active IP Right Cessation
- 2013-05-02 MX MX2014013271A patent/MX345540B/es active IP Right Grant
- 2013-05-02 CA CA2872109A patent/CA2872109C/en active Active
- 2013-05-02 CN CN201380035279.0A patent/CN104412270B/zh not_active Expired - Fee Related
- 2013-05-02 EP EP13784507.9A patent/EP2847701A4/en not_active Ceased
- 2013-05-02 RU RU2014148543A patent/RU2014148543A/ru not_active Application Discontinuation
- 2013-05-02 WO PCT/US2013/039189 patent/WO2013166233A1/en active Application Filing
- 2013-05-02 SG SG11201407141VA patent/SG11201407141VA/en unknown
- 2013-05-02 JP JP2015510444A patent/JP6365988B2/ja active Active
- 2013-05-02 BR BR112014027287A patent/BR112014027287A2/pt not_active Application Discontinuation
-
2014
- 2014-10-31 NI NI201400128A patent/NI201400128A/es unknown
- 2014-11-02 IL IL235455A patent/IL235455B/en not_active IP Right Cessation
- 2014-11-03 CL CL2014002981A patent/CL2014002981A1/es unknown
- 2014-11-03 CU CU2014000125A patent/CU20140125A7/es unknown
- 2014-12-02 CO CO14265404A patent/CO7190233A2/es unknown
- 2014-12-02 PH PH12014502687A patent/PH12014502687A1/en unknown
- 2014-12-02 CR CR20140551A patent/CR20140551A/es unknown
-
2015
- 2015-05-04 HK HK15104231.4A patent/HK1203670A1/xx unknown
-
2016
- 2016-10-04 US US15/285,292 patent/US10488402B2/en active Active
-
2018
- 2018-12-21 AU AU2018282460A patent/AU2018282460B2/en active Active
-
2019
- 2019-10-02 US US16/591,389 patent/US20200249222A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7190233A2 (es) | Sistema y método para la determinación automatizada de la efectividad relativa de candidatos de fármaco anti-cancerígenos | |
| GB2547355A (en) | System and method for collection, storage and management of medical data | |
| BR112018009606A2 (pt) | construção de alta eficiência de bibliotecas de dna | |
| CR20150552A (es) | Entorno de aprendizaje de idiomas | |
| BR112016008970A2 (pt) | Método de ativação ex vivo e para avaliar ativação plasmática em um indivíduo, ensaio ex vivo para determinar atividade de calicreína plasmática em uma amostra | |
| AR095894A1 (es) | Sistema y método para facilitar la asistencia en situaciones de emergencia | |
| MX2016009060A (es) | Metodos y sistemas para determinar el riesgo de falla cardiaca. | |
| BR112016013383A2 (pt) | Método para avaliar um evento de alarme, sistema de monitoramento fisiológico e método para avaliar um único evento de alarme | |
| AR091091A1 (es) | Modelado estratigrafico utilizando perfiles de densidad de datos de produccion | |
| AR091307A1 (es) | Identificacion de relojes y sistema y metodo de autenticacion | |
| PE20170646A1 (es) | Sistema de evaluacion de riesgos para sistema de proceso, programa de evaluacion de riesgos y metodos de evaluacion de riesgos | |
| BR112017021298A2 (pt) | sistemas, mídia de armazenamento não transitório, e método | |
| WO2014165003A8 (en) | Systems and methods for fluid analysis using electromagnetic energy | |
| CL2016001965A1 (es) | Composición coadyuvante anticancerígena que contiene rip3 expresión del promotor como ingrediente activo, método para seleccionar composición coadyuvante anticancerígena para mejorar la sensibilidad de droga anticancerigena, promoviendo la expresión rip3, y metodo para seguimiento de sensibilidad; medicamento contra el cáncer | |
| BR112017003751A2 (pt) | medida e diagnóstico de ruído em ambiente urbano | |
| BR112015019567A2 (pt) | marcadores associados com inibidores de wnt | |
| AR088276A1 (es) | Fenotipificacion de precision usando analisis de proximidad del espacio de puntuacion | |
| AR104805A1 (es) | Métodos y composiciones para evaluar la capacidad de respuesta de los cánceres a los inhibidores de bet | |
| CL2013002421A1 (es) | Un sistema y metodo para distribuir alertas con respecto a un evento. | |
| Yıldırım et al. | The relation between pain perceived by the patients hospitalized in the algology clinic and their sleep and quality of life | |
| AR102226A1 (es) | Métodos para personalizar la terapia contra el cáncer de un paciente con un antagonista de mdm2 | |
| Lin et al. | Alteration of anterior chamber and angle structure in eyes with primary angle closure after laser peripheral iridotomy | |
| Abaurre et al. | Design and piloting of a structured service medication dispensing process | |
| AR107780A1 (es) | Método para determinar la actividad de enfermedades autoinmunes y kit | |
| Taino et al. | Judgment of fitness for work in employees with a history of malignant neoplastic disease and exposed to ionizing radiations: Evaluation criteria and their application in a case-series study |